Active polysaccharide-containing medicine having effect of reducing high uric acid and preparation method of active polysaccharide-containing medicine

A technology of active polysaccharides and drugs, applied in the field of medicine, can solve problems such as damage to the liver nervous system, toxic side effects, skin allergies, etc., and achieve the effects of reducing gastric ulcer symptoms, relieving gout, and accelerating wound healing

Pending Publication Date: 2020-12-04
SHANGHAI UNIV OF MEDICINE & HEALTH SCI
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the commonly used clinical drugs include non-steroidal anti-inflammatory drugs, colchicine, glucocorticoids, probenecid, benzomarone, and allopurinol. The therapeutic effect is remarkable, but they all have different degrees of side effects and adverse reactions. Damage the liver, nervous system, cause skin allergies, life-threatening hypersensitivity allergies, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Active polysaccharide-containing medicine having effect of reducing high uric acid and preparation method of active polysaccharide-containing medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] An active polysaccharide-containing drug with the effect of lowering uric acid, the active polysaccharide-containing drug includes the following components in parts by weight: 8 parts of marine fish oligopeptide powder, 5 parts of yew polysaccharide, 7 parts of papaya, and 6 parts of Agkistrodon halys , 7 parts of coix seed, 11 parts of celery powder, 11 parts of burdock root powder, 1 part of corn silk powder, 3 parts of chlorella pyrenoidosa powder, 6 parts of vitamin A, 11 parts of flavor enhancer, and 5 parts of Phellinus.

[0025] The preparation method of the above active polysaccharide-containing drug comprises the following steps:

[0026] S1. Weigh the papaya and Agkistrodon halys in parts by weight, add 12 times the amount of water, heat and extract twice, each time for 2 hours, filter, combine the filtrate, concentrate the filtrate to 65°C and measure the clear paste with a relative density of 1.2; Take the coix seed by weight, grind it into fine powder, and ...

Embodiment 2

[0029] An active polysaccharide-containing drug with the effect of lowering uric acid, the active polysaccharide-containing drug includes the following components in parts by weight: 11 parts of marine fish oligopeptide powder, 8 parts of yew polysaccharide, 12 parts of papaya, and 9 parts of Agkistrodon halys , 12 parts of coix seed, 18 parts of celery powder, 16 parts of burdock root powder, 7 parts of corn silk powder, 10 parts of chlorella pyrenoidosa powder, 11 parts of vitamin B111, 25 parts of excipients, and 9 parts of Phellinus.

[0030] The preparation method of the above active polysaccharide-containing drug comprises the following steps:

[0031] S1. Weigh the papaya and Agkistrodon halys by weight, add 13 times the amount of water, heat and extract 3 times, each time for 2.5 hours, filter, combine the filtrate, concentrate the filtrate to 70°C and measure the clear paste with a relative density of 1.3; Take the coix seed by weight, grind it into fine powder, and p...

Embodiment 3

[0034] An active polysaccharide-containing drug with the effect of lowering uric acid, the active polysaccharide-containing drug includes the following components by weight: 15 parts of marine fish oligopeptide powder, 12 parts of yew polysaccharide, 15 parts of papaya, and 11 parts of Pit Viper , Coix seed 13 parts, celery powder 20 parts, burdock root powder 19 parts, corn silk powder 15 parts, chlorella pyrenoidosa powder 16 parts, niacin 19 parts, stabilizer 30 parts, Phellinus 15 parts.

[0035] The preparation method of the above active polysaccharide-containing drug comprises the following steps:

[0036] S1. Weigh the papaya and Agkistrodon halys by weight, add 15 times the amount of water, heat and extract 3 times, each time for 3 hours, filter, combine the filtrate, concentrate the filtrate to 75 ° C, and measure the clear paste with a relative density of 1.4; Take the coix seed by weight, grind it into fine powder, and pass through a 90-mesh sieve;

[0037] S2. Wei...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an active polysaccharide-containing medicine having effect of reducing high uric acid and a preparation method of the active polysaccharide-containing medicine. The active polysaccharide-containing medicine comprises the following components in parts by weight: 8-15 parts of marine fish oligopeptide powder, 5-12 parts of Chinese yew polysaccharide, 7-15 parts of papayas, 6-11 parts of pallas pit viper, 7-13 parts of coix seeds, 11-20 parts of celery powder, 11-19 parts of burdock root powder, 1-15 parts of corn stigma powder, 3-16 parts of chlorella pyrenoidosa powder,6-19 parts of vitamins, 11-30 parts of edible auxiliary materials and 5-15 parts of phellinus igniarius. All the raw materials of the active polysaccharide-containing medicine have a synergistic effect, and the effect of reducing uric acid is remarkable.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to an active polysaccharide-containing drug with the effect of lowering uric acid and a preparation method thereof. Background technique [0002] Uric acid is the end product of purine metabolism in the human body. The daily production and excretion of uric acid in the body are approximately equal. However, when the purine metabolism in the body is disturbed, the uric acid content will increase. Due to the low solubility of uric acid, excessive uric acid in the body can form a urinary tract Stones or gout. Hyperuricemia refers to a body state in which the concentration of uric acid in the blood exceeds the normal range. It is generally believed that when the concentration of uric acid in the blood of men is greater than 400 μmol / L, and that of women is greater than 360 μmol / L, hyperuricemia should be considered. blood disease. Recent studies have shown that hyperuricemia is not o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/01A61P19/06A23L33/125A23L33/18A23L7/10A23L19/00A23L33/10A23L33/00A23L13/00A61K31/07A61K31/455A61K31/519A61K31/715A61K35/583A61K36/8994
CPCA61K38/012A61K31/715A61K36/732A61K35/583A61K36/8994A61K36/23A61K36/28A61K36/899A61K36/05A61K36/07A61K31/07A61K31/519A61K31/455A61P19/06A23L33/125A23L33/18A23L7/10A23L19/00A23L33/10A23L33/00A23L13/00A23V2002/00A61K2300/00A23V2200/30A23V2250/70A23V2250/51
Inventor 李婷婷费韶翔于国阳孙纪新
Owner SHANGHAI UNIV OF MEDICINE & HEALTH SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap